Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Acquired hemophilia a


Published on

Acquired Hemophilia A

Published in: Healthcare
  • Be the first to comment

Acquired hemophilia a

  2. 2. ACQUIRED HEMOPHILIA A CHARACTERISTICS Incidence 0.2-1.0 case per million per year – is incidence increasing??? 80-90% present with major hemorrhages 10-22% mortality attributed to inhibitor Biphasic age distribution  Small peak in young postpartum women  Major peak in 60-80 years of age
  3. 3. ACQUIRED HEMOPHILIA A CHARACTERISTICS  Most individuals are previously healthy-idiopathic.  Some have defined or evolving associations.
  4. 4. CLINICAL MANIFESTATIONS OF ACQUIRED HEMOPHILIA  Overt bleeding -most frequently bruising, muscle hematomas, GI bleeding, hematuria  Iatrogenic - IV lines, bladder catheterization or post surgical bleeding  Acute complications - compartment syndromes, airway compression 2nd to subglottic bleeding  Values of more than 5 BU/ml are defined as high titer inhibitors and are generally associated with more aggressive bleeding and delayed responses to treatment .
  5. 5. FVIII INHIBITORS INACTIVATE FVIII AAuuttooaannttiibbooddyy IInnaaccttiivvaattiioonn KKiinneettiiccss • DDiissppllaayy ttyyppee IIII kkiinneettiiccss • CClleeaarraannccee iiss nnoott lliinneeaarr • DDiiffffiiccuulltt ttoo ““oovveerrwwhheellmm”” wwiitthh cclloottttiinngg ffaaccttoorr rreeppllaacceemmeenntt Boggio, LN, Green D. Rev Clin Exp Hematol. 2001;5:389-404
  7. 7. CLINICAL FEATURES OF BLEEDING DISORDERS Platelet Factor Disorders Coagulation disorders Site of bleeding Skin, Mucous membranes (epistaxis, gum, vaginal, GI tract) Deep in soft tissues (joints, muscles) Petechiae Yes No Ecchymoses (“bruises”) Small, superficial Large, deep Hemarthrosis / muscle bleeding Extremely rare Common Bleeding after cuts & scratches Yes No Bleeding after surgery or trauma Immediate Delayed (1-2 days)
  8. 8. Platelet Coagulation Purpura Ecchymoses Petechiae
  10. 10. Look at Thrombin Time!!!
  11. 11. When you see isolated PROLONGED aPTT, the next test to order is…… aPTT MIXING STUDY!!!!
  12. 12. PTT MIXING STUDIES:  Mixing studies are tests performed on blood plasma used to distinguish factor deficiencies from factor inhibitors, such as lupus anticoagulant (LA), or specific factor inhibitors, such as antibodies directed against factor VIII.
  13. 13. PTT MIXING STUDIES:  Mixing studies take advantage of the fact that factor levels that are 50 percent of normal should give a normal Prothrombin time (PT) or Partial Thromboplastin time.
  14. 14. PTT MIXING STUDIES:  Mixing studies can help determine the appropriate next steps to take to diagnose the cause of an abnormal APTT or PT.
  15. 15. TEST METHOD  The patient plasma is mixed 1:1 with Normal pooled plasma that contains 100% of the normal factor level results in a level ≥ 50% in the mixture (say the patient has an activity of 0%; the average of 100% + 0% = 50%).  Therefore, correction with mixing indicates factor deficiency; failure to correct indicates an inhibitor.
  16. 16. TEST METHOD  Some inhibitors are time dependent. The clotting test performed immediately after the specimens are mixed may show correction because the antibody has not had time to inactivate the added factor (false positive). A test performed after the mixture is incubated for 2 hours at 37°C will show prolongation.  Nonspecific inhibitors like the lupus anticoagulant usually are not time dependent; the immediate mixture will show prolongation.  Many specific factor inhibitors are time dependent, and the inhibitor will not be detected unless the test is repeated after incubation (factor VIII inhibitors are notorious for this).
  17. 17. INTERPRETATION Differentiation of Factor Deficiency and Inhibitors By Mixing Studies 1:1 Mixing Study Results Not incubated Incubated Factor deficiency Correction Correction Immediate acting inhibitor No correction No correction Time/temperature dependent inhibitor Correction (Falsely) No correction Table adapted from McKenzie, S.,, Clinical l Laboratory Hematology, 2004, p. 790.
  19. 19. THE BETHESDA UNIT One Bethesda Unit: The amount of antibody that inhibits half of the factor VIII activity in a 1 to 1 mixture of patient plasma and normal plasma incubated at 37°C for 2 hours Kasper, 1975
  20. 20. Treatment of Bleeding in Factor VIII Autoantibodies-Control Bleeding and Eliminate Inhibitors For patients with non life-threatening bleeding and low inhibitor titers, DDAVP at a dose of 0.3 mcg/kg SQ per day given for three to five days may be sufficient for control of bleeding or for hemostatic coverage of invasive procedures .
  21. 21. Treatment of Bleeding in Factor VIII Autoantibodies-Control Bleeding and Eliminate Inhibitors Most bleeding associated with low titer inhibitors (ie, <5 Bethesda units) may be treated with human factor VIII concentrates at high doses (eg, 20 IU/kg for each Bethesda unit of the inhibitor plus an additional 40 IU/kg, with monitoring of factor VIII activity 10 minutes following bolus injection, and repeat IV bolus dosing if the incremental recovery is not adequate).
  22. 22. Treatment of Bleeding in Factor VIII Autoantibodies- Control Bleeding and Eliminate Inhibitors  For patients with higher titer factor VIII inhibitors (>5 BU) or severe bleeding, treatment with activated prothrombin complex (eg, factor VIII inhibitor bypassing activity [FEIBA]) or human recombinant human factor VIIIa (rfVIIa) can be employed.  Bypassing agents achieve an 86% control in all bleeding types and a 76% control in severe bleedings.  Recommended doses are similar to those employed in hemophilia patients with inhibitors (eg, typical FEIBA dose 75 units/kg; rfVIIa median starting dose 90.4 mcg/kg, range 45 to 181 mcg/kg).
  23. 23. NovoSeven® (rFVIIa) controls bleeding at the site of vascular injury only1 rFVIIa works locally at the site of vascular injury, where tissue factor (TF) is exposed and activated platelets are found1 Binding of factor VIIa or rFVIIa to TF initiates the coagulation generating small amounts of thrombin2  At pharmacological doses rFVIIa directly activates factor X on the surface of activated platelets resulting in a “thrombin burst”3,4  The thrombin burst leads to the formation of a stable haemostatic plug which controls the bleeding3  Haemostasis and NovoSeven® – mode of action; Feb 2006 Adapted from Hoffman M et al., 2001.1
  24. 24. Side Effects of Treatment of Bleeding in Autoantibodies Recombinant FVIIa - Thrombosis (< 2%) FEIBA and Autoplex Thrombosis Allergic Reactions Low risk for transmission of infectious agents
  25. 25. Arterial and Fatal Thromboembolic SAEs DATA from ICH Study  Arterial thromboembolic SAEs occurred significantly (P = 0.01) more frequently with rFVIIa treatment (5%) than with placebo (0%) These events manifested in the form of myocardial ischemic events (7) and cerebral infarction (9)  Thromboembolic SAEs that were fatal or disabling occurred in 2% of rFVIIa-treated patients compared with 2% in the placebo group Mayer SA et al. N Engl J Med. 2005;352:777-785.
  26. 26. Management of Autoantibody to Factor VIII  Immunosuppressive Medications  Immediate initiation of immunosuppressive therapy after confirmation of AHA diagnosis is recommended. Prednisone 60 mg/day x 3-6 wks Work better in low titer, new inhibitors with no associated disease  Others Combined Rx - prednisone plus cyclophosphamide Cyclosporine, tacrolimus, azathioprine, mycophenolate mofetil, interferon a. Rituximab has been used in refractory cases in a dose of 375 mg/m2 every week for 4 weeks.
  27. 27. Management of Autoantibody to Factor VIII  The above therapies have been shown to achieve a complete remission (CR) rate of inhibitor eradication between 52- 82%.  Complete remission is defined as normal Factor VIII activity (70%-140%) without factor substitution and undetectable inhibitor titer levels.  Partial remission can be defined as attaining a minimum of FVIII recoveries of 30% and/or a reduction of the inhibitor titer to less than 5 BU without further bleeding events.
  28. 28. TREATMENT There is no evidence that one immunosuppressive therapy is clinically superior to all others in treating AHA or that a certain therapy should be chosen depending on inhibitor titer or the hemorrhagic status. Therefore, first-line treatment is determined by evaluation of disease condition and consideration of possible adverse effects.
  29. 29. MANAGEMENT OF AUTOANTIBODY TO FACTOR VIII Physical removal of inhibitors by plasma exchange therapy or protein A adsorption column is effective for transient removal of inhibitors in patients with acute, severe bleeding.
  30. 30. MODIFIED BONN MALMÖ PROTOCOL (MBMP) 1. Large-volume immunoadsorption (IA) (2.5-3x total plasma volume on days 1-5) 2. I.v. IgG substitution (0.3 g/kg body weight (BW)/d, on days 5- 7) 3. Immunosuppression with cyclophosphamide (1-2 mg/kg BW/d) and prednisolone (1 mg/kg BW/d) from day 1 until remission (dose reduction), 4. Administration of FVIII, typically 100 IU/kg BW every 6 hours. Zeitler H et al. Atheroscler Suppl. 2009 Dec 29;10(5):122-5.
  31. 31. MONITORING RESPONSE TO TREATMENT  Primary goal of treatment is cessation of bleeding, followed ultimately by a decrease in the titer of the inhibitor.  The former is monitored via the usual clinical and laboratory observations (eg, observable blood loss, blood in urine or stool, repeated blood counts).  Since inhibitor titers drop very slowly following successful treatment, it is neither necessary nor advisable to check the patient’s aPTT or inhibitor titer more often than every two to four weeks once immunosuppressive therapy has been started.
  32. 32. SUMMARY  When encountered with a bleeding elderly patient with isolated prolonged PTT-think coagulation factor inhibitors vs acquired VWD vs Lupus Anticoagulant (associated more with thrombosis).  If thrombin time is normal, heparin as the etiology for prolonged PTT less likely.  Call the lab and expedite PTT Mixing study.  Make sure the lab does the delayed phase of the PTT Mixing Study.  Treat bleeding aggressively with bypass agents and immunosuppressives simultaneously.  Immunoadsorption is a safe and highly effective alternative with a high potential to cure severe AH.